Alaunos Therapeutics, Inc. Stock price

Equities

TCRT

US98973P2002

Biotechnology & Medical Research

Delayed Nasdaq 03:52:42 2024-03-28 pm EDT 5-day change 1st Jan Change
1.806 USD -2.93% Intraday chart for Alaunos Therapeutics, Inc. -5.74% +70.66%
Sales 2023 * 4K Sales 2024 * - Capitalization 29.78M
Net income 2023 * -35M Net income 2024 * -9M EV / Sales 2023 * 7,446 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-0.83 x
P/E ratio 2024 *
-3.1 x
Employees 34
Yield 2023 *
-
Yield 2024 *
-
Free-Float 95.6%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.70%
1 week-5.74%
Current month-13.41%
1 month-22.99%
3 months+74.10%
6 months-8.04%
Current year+70.66%
More quotes
1 week
1.79
Extreme 1.7908
1.98
1 month
1.51
Extreme 1.51
2.32
Current year
1.01
Extreme 1.008
3.29
1 year
0.66
Extreme 0.66
10.47
3 years
0.66
Extreme 0.66
60.15
5 years
0.66
Extreme 0.66
108.75
10 years
0.66
Extreme 0.66
223.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 Dec. 28
Director of Finance/CFO 62 21-02-16
Chief Tech/Sci/R&D Officer 44 22-08-03
Members of the board TitleAgeSince
Director/Board Member 54 20-12-15
Chairman 61 20-12-15
Director/Board Member 70 21-02-04
More insiders
Date Price Change Volume
24-03-28 1.806 -2.93% 67 960
24-03-27 1.86 -1.59% 24,730
24-03-26 1.89 -1.05% 27,835
24-03-25 1.91 +2.69% 59,691
24-03-22 1.86 -3.12% 61,788

Delayed Quote Nasdaq, March 28, 2024 at 03:52 pm EDT

More quotes
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. It is engaged in developing adoptive TCR engineered T-cell therapies (TCR-T), designed to treat multiple solid tumor types in large cancer patient populations. It is leveraging its cancer mutation hotspot TCR library and its non-viral Sleeping Beauty genetic engineering technology to design and manufacture patient-specific cell therapies that target neoantigens arising from common tumor-related mutations in oncogenic genes, including KRAS, TP53 and EGFR. Its TCR library consists of ten TCRs targeting six solid tumor indications, such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers. Using its human neoantigen T cell Receptor discovery engine, it analyzes thousands of single T cells simultaneously using bioinformatics and next generation sequencing. Its pipeline in cell therapy for oncology consists of Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.86
Average target price
-
Consensus
  1. Stock
  2. Equities
  3. Stock Alaunos Therapeutics, Inc. - Nasdaq